{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:33:32Z","timestamp":1791851612206,"version":"4.3.4"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100016645","name":"Shear Family Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016645","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Magee Womens Research Institute and Foundation"},{"name":"UPMC Hillman Cancer Center and Tissue and Research Pathology\/Pitt Biospecimen Core and the Biostatistics Core shared resources","award":["P30CA047904"],"award-info":[{"award-number":["P30CA047904"]}]},{"name":"NIH","award":["CA224909"],"award-info":[{"award-number":["CA224909"]}]},{"DOI":"10.13039\/100009634","name":"Susan G Komen","doi-asserted-by":"crossref","award":["SAC160073"],"award-info":[{"award-number":["SAC160073"]}],"id":[{"id":"10.13039\/100009634","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s10549-025-07666-x","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T16:45:39Z","timestamp":1742229939000},"page":"501-515","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["FGFR4 in endocrine resistance: overexpression and estrogen regulation without direct causative role"],"prefix":"10.1007","volume":"211","author":[{"given":"Kai","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyuqin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin M.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Sikora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilgun","family":"Tasdemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dabbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Jankowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Hazan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Atkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian V.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffi","family":"Oesterreich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,17]]},"reference":[{"issue":"2","key":"7666_CR1","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s40487-018-0062-x","volume":"6","author":"SJ Johnston","year":"2018","unstructured":"Johnston SJ, Cheung KL (2018) Endocrine therapy for breast cancer: a model of hormonal manipulation. Oncol Ther 6(2):141\u2013156","journal-title":"Oncol Ther"},{"issue":"47","key":"7666_CR2","doi-asserted-by":"publisher","first-page":"7316","DOI":"10.1038\/sj.onc.1206937","volume":"22","author":"R Clarke","year":"2003","unstructured":"Clarke R, Liu MC, Bouker KB, Gu Z, Lee RY, Zhu Y, Skaar TC, Gomez B, O\u2019Brien K, Wang Y et al (2003) Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 22(47):7316\u20137339","journal-title":"Oncogene"},{"key":"7666_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2015.09.035","author":"R Clarke","year":"2015","unstructured":"Clarke R, Tyson JJ, Dixon JM (2015) Endocrine resistance in breast cancer\u2013an overview and update. Mol Cell Endocrinol. https:\/\/doi.org\/10.1016\/j.mce.2015.09.035","journal-title":"Mol Cell Endocrinol"},{"issue":"2","key":"7666_CR4","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/joim.12084","volume":"274","author":"AJ Redig","year":"2013","unstructured":"Redig AJ, McAllister SS (2013) Breast cancer as a systemic disease: a view of metastasis. J Intern Med 274(2):113\u2013126","journal-title":"J Intern Med"},{"issue":"4","key":"7666_CR5","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.ccell.2020.03.009","volume":"37","author":"AB Hanker","year":"2020","unstructured":"Hanker AB, Sudhan DR, Arteaga CL (2020) Overcoming endocrine resistance in breast cancer. Cancer Cell 37(4):496\u2013513","journal-title":"Cancer Cell"},{"issue":"8","key":"7666_CR6","doi-asserted-by":"publisher","first-page":"R337","DOI":"10.1530\/ERC-16-0121","volume":"23","author":"CG Murphy","year":"2016","unstructured":"Murphy CG, Dickler MN (2016) Endocrine resistance in hormone-responsive breast cancer: mechanisms and therapeutic strategies. Endocr Relat Cancer 23(8):R337-352","journal-title":"Endocr Relat Cancer"},{"key":"7666_CR7","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1146\/annurev-med-070909-182917","volume":"62","author":"CK Osborne","year":"2011","unstructured":"Osborne CK, Schiff R (2011) Mechanisms of endocrine resistance in breast cancer. Annu Rev Med 62:233\u2013247","journal-title":"Annu Rev Med"},{"key":"7666_CR8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41523-019-0114-x","volume":"5","author":"KM Levine","year":"2019","unstructured":"Levine KM, Priedigkeit N, Basudan A, Tasdemir N, Sikora MJ, Sokol ES, Hartmaier RJ, Ding K, Ahmad NZ, Watters RJ et al (2019) FGFR4 overexpression and hotspot mutations in metastatic ER+ breast cancer are enriched in the lobular subtype. NPJ Breast Cancer 5:19","journal-title":"NPJ Breast Cancer"},{"issue":"9","key":"7666_CR9","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1158\/0008-5472.CAN-16-2717","volume":"77","author":"JM Cejalvo","year":"2017","unstructured":"Cejalvo JM, Mart\u00ednez de Due\u00f1as E, Galv\u00e1n P, Garc\u00eda-Recio S, Burgu\u00e9s Gasi\u00f3n O, Par\u00e9 L, Antol\u00edn S, Martinello R, Blancas I, Adamo B et al (2017) Intrinsic subtypes and gene expression profiles in primary and metastatic breast cancer. Cancer Res 77(9):2213\u20132221","journal-title":"Cancer Res"},{"issue":"20","key":"7666_CR10","doi-asserted-by":"publisher","first-page":"5165","DOI":"10.1158\/1078-0432.CCR-18-0279","volume":"24","author":"AM Nagle","year":"2018","unstructured":"Nagle AM, Levine KM, Tasdemir N, Scott JA, Burlbaugh K, Kehm J, Katz TA, Boone DN, Jacobsen BM, Atkinson JM et al (2018) Loss of E-cadherin enhances IGF1-IGF1R pathway activation and sensitizes breast cancers to anti-IGF1R\/InsR inhibitors. Clin Cancer Res 24(20):5165\u20135177","journal-title":"Clin Cancer Res"},{"key":"7666_CR11","first-page":"81","volume":"27","author":"A Elangovan","year":"2022","unstructured":"Elangovan A, Hooda J, Savariau L, Puthanmadhomnarayanan S, Yates ME, Chen J, Brown DD, McAuliffe PF, Oesterreich S, Atkinson JM et al (2022) Loss of E-cadherin Induces IGF1R activation and reveals a targetable pathway in invasive lobular breast carcinoma. Mol Cancer Res 27:81","journal-title":"Mol Cancer Res"},{"issue":"1","key":"7666_CR12","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1677\/ERC-07-0080","volume":"15","author":"D Meijer","year":"2008","unstructured":"Meijer D, Sieuwerts AM, Look MP, van Agthoven T, Foekens JA, Dorssers LC (2008) Fibroblast growth factor receptor 4 predicts failure on tamoxifen therapy in patients with recurrent breast cancer. Endocr Relat Cancer 15(1):101\u2013111","journal-title":"Endocr Relat Cancer"},{"key":"7666_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107590","volume":"214","author":"KM Levine","year":"2020","unstructured":"Levine KM, Ding K, Chen L, Oesterreich S (2020) FGFR4: a promising therapeutic target for breast cancer and other solid tumors. Pharmacol Ther 214:107590","journal-title":"Pharmacol Ther"},{"issue":"2","key":"7666_CR14","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/nrc2780","volume":"10","author":"N Turner","year":"2010","unstructured":"Turner N, Grose R (2010) Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 10(2):116\u2013129","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"7666_CR15","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s003359900703","volume":"9","author":"M Kostrzewa","year":"1998","unstructured":"Kostrzewa M, M\u00fcller U (1998) Genomic structure and complete sequence of the human FGFR4 gene. Mamm Genome 9(2):131\u2013135","journal-title":"Mamm Genome"},{"issue":"4","key":"7666_CR16","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1158\/2159-8290.CD-14-1029","volume":"5","author":"M Hagel","year":"2015","unstructured":"Hagel M, Miduturu C, Sheets M, Rubin N, Weng W, Stransky N, Bifulco N, Kim JL, Hodous B, Brooijmans N et al (2015) First selective small molecule inhibitor of FGFR4 for the treatment of hepatocellular carcinomas with an activated FGFR4 signaling pathway. Cancer Discov 5(4):424\u2013437","journal-title":"Cancer Discov"},{"issue":"24","key":"7666_CR17","doi-asserted-by":"publisher","first-page":"6999","DOI":"10.1158\/0008-5472.CAN-17-1865","volume":"77","author":"JJ Joshi","year":"2017","unstructured":"Joshi JJ, Coffey H, Corcoran E, Tsai J, Huang CL, Ichikawa K, Prajapati S, Hao MH, Bailey S, Wu J et al (2017) H3B\u20136527 Is a potent and selective inhibitor of FGFR4 in FGF19-driven hepatocellular carcinoma. Cancer Res 77(24):6999\u20137013","journal-title":"Cancer Res"},{"key":"7666_CR18","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2017-1234","author":"B Ruggeri","year":"2017","unstructured":"Ruggeri B, Stubbs M, Yang Y-o, Juvekar A, Lu L, Condon S, DiMatteo D, Wen X, Collier P, Burn T et al (2017) Abstract 1234: the novel FGFR4-selective inhibitor INCB062079 is efficacious in models of hepatocellular carcinoma harboring FGF19 amplification. Cancer Res. https:\/\/doi.org\/10.1158\/1538-7445.AM2017-1234","journal-title":"Cancer Res"},{"key":"7666_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115947","volume":"263","author":"X Chen","year":"2024","unstructured":"Chen X, Huang Y, Chen B, Liu H, Cai Y, Yang Y (2024) Insight into the design of FGFR4 selective inhibitors in cancer therapy: prospects and challenges. Eur J Med Chem 263:115947","journal-title":"Eur J Med Chem"},{"issue":"3","key":"7666_CR20","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/nrm3528","volume":"14","author":"R Goetz","year":"2013","unstructured":"Goetz R, Mohammadi M (2013) Exploring mechanisms of FGF signalling through the lens of structural biology. Nat Rev Mol Cell Biol 14(3):166\u2013180","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"7","key":"7666_CR21","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/35083041","volume":"3","author":"U Cavallaro","year":"2001","unstructured":"Cavallaro U, Niedermeyer J, Fuxa M, Christofori G (2001) N-CAM modulates tumour-cell adhesion to matrix by inducing FGF-receptor signalling. Nat Cell Biol 3(7):650\u2013657","journal-title":"Nat Cell Biol"},{"issue":"15","key":"7666_CR22","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1097\/WNR.0b013e3283491682","volume":"22","author":"C Christensen","year":"2011","unstructured":"Christensen C, Berezin V, Bock E (2011) Neural cell adhesion molecule differentially interacts with isoforms of the fibroblast growth factor receptor. NeuroReport 22(15):727\u2013732","journal-title":"NeuroReport"},{"issue":"52","key":"7666_CR23","doi-asserted-by":"publisher","first-page":"18866","DOI":"10.1073\/pnas.0509741102","volume":"102","author":"H Yokote","year":"2005","unstructured":"Yokote H, Fujita K, Jing X, Sawada T, Liang S, Yao L, Yan X, Zhang Y, Schlessinger J, Sakaguchi K (2005) Trans-activation of EphA4 and FGF receptors mediated by direct interactions between their cytoplasmic domains. Proc Natl Acad Sci U S A 102(52):18866\u201318871","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"36","key":"7666_CR24","doi-asserted-by":"publisher","first-page":"15786","DOI":"10.1073\/pnas.0914459107","volume":"107","author":"N Sugiyama","year":"2010","unstructured":"Sugiyama N, Varjosalo M, Meller P, Lohi J, Chan KM, Zhou Z, Alitalo K, Taipale J, Keski-Oja J, Lehti K (2010) FGF receptor-4 (FGFR4) polymorphism acts as an activity switch of a membrane type 1 matrix metalloproteinase-FGFR4 complex. Proc Natl Acad Sci U S A 107(36):15786\u201315791","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5\u20136","key":"7666_CR25","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1159\/000335472","volume":"81","author":"AL Cheng","year":"2011","unstructured":"Cheng AL, Shen YC, Zhu AX (2011) Targeting fibroblast growth factor receptor signaling in hepatocellular carcinoma. Oncology 81(5\u20136):372\u2013380","journal-title":"Oncology"},{"issue":"1","key":"7666_CR26","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.jhep.2008.08.015","volume":"50","author":"HK Ho","year":"2009","unstructured":"Ho HK, Pok S, Streit S, Ruhe JE, Hart S, Lim KS, Loo HL, Aung MO, Lim SG, Ullrich A (2009) Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention. J Hepatol 50(1):118\u2013127","journal-title":"J Hepatol"},{"key":"7666_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/cells8060536","author":"A Raja","year":"2019","unstructured":"Raja A, Park I, Haq F, Ahn SM (2019) FGF19-FGFR4 signaling in hepatocellular carcinoma. Cells. https:\/\/doi.org\/10.3390\/cells8060536","journal-title":"Cells"},{"issue":"14","key":"7666_CR28","doi-asserted-by":"publisher","first-page":"3780","DOI":"10.1158\/1078-0432.CCR-10-3063","volume":"18","author":"LE Crose","year":"2012","unstructured":"Crose LE, Etheridge KT, Chen C, Belyea B, Talbot LJ, Bentley RC, Linardic CM (2012) FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma. Clin Cancer Res 18(14):3780\u20133790","journal-title":"Clin Cancer Res"},{"issue":"11","key":"7666_CR29","first-page":"3395","volume":"119","author":"JGT Vi","year":"2009","unstructured":"Vi JGT, Cheuk AT, Tsang PS, Chung JY, Song YK, Desai K, Yu Y, Chen QR, Shah K, Youngblood V, Fang J (2009) Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. J Clin Invest 119(11):3395\u20133407","journal-title":"J Clin Invest"},{"issue":"1","key":"7666_CR30","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/2049-3002-1-21","volume":"1","author":"Y Luo","year":"2013","unstructured":"Luo Y, Yang C, Ye M, Jin C, Abbruzzese JL, Lee MH, Yeung SC, McKeehan WL (2013) Deficiency of metabolic regulator FGFR4 delays breast cancer progression through systemic and microenvironmental metabolic alterations. Cancer Metab 1(1):21","journal-title":"Cancer Metab"},{"issue":"36","key":"7666_CR31","doi-asserted-by":"publisher","first-page":"57633","DOI":"10.18632\/oncotarget.9328","volume":"7","author":"KH Tiong","year":"2016","unstructured":"Tiong KH, Tan BS, Choo HL, Chung FF, Hii LW, Tan SH, Khor NT, Wong SF, See SJ, Tan YF et al (2016) Fibroblast growth factor receptor 4 (FGFR4) and fibroblast growth factor 19 (FGF19) autocrine enhance breast cancer cells survival. Oncotarget 7(36):57633\u201357650","journal-title":"Oncotarget"},{"issue":"1","key":"7666_CR32","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1159\/000489759","volume":"47","author":"M Xu","year":"2018","unstructured":"Xu M, Chen S, Yang W, Cheng X, Ye Y, Mao J, Wu X, Huang L, Ji J (2018) FGFR4 links glucose metabolism and chemotherapy resistance in breast cancer. Cell Physiol Biochem 47(1):151\u2013160","journal-title":"Cell Physiol Biochem"},{"issue":"10","key":"7666_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0076551","volume":"8","author":"SQ Li","year":"2013","unstructured":"Li SQ, Cheuk AT, Shern JF, Song YK, Hurd L, Liao H, Wei JS, Khan J (2013) Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534). PLoS ONE 8(10):e76551","journal-title":"PLoS ONE"},{"issue":"9","key":"7666_CR34","doi-asserted-by":"publisher","first-page":"4871","DOI":"10.1172\/JCI130323","volume":"130","author":"S Garcia-Recio","year":"2020","unstructured":"Garcia-Recio S, Thennavan A, East MP, Parker JS, Cejalvo JM, Garay JP, Hollern DP, He X, Mott KR, Galv\u00e1n P et al (2020) FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease. J Clin Invest 130(9):4871\u20134887","journal-title":"J Clin Invest"},{"key":"7666_CR35","doi-asserted-by":"publisher","first-page":"12498","DOI":"10.1038\/ncomms12498","volume":"7","author":"CA Miller","year":"2016","unstructured":"Miller CA, Gindin Y, Lu C, Griffith OL, Griffith M, Shen D, Hoog J, Li T, Larson DE, Watson M et al (2016) Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers. Nat Commun 7:12498","journal-title":"Nat Commun"},{"issue":"20","key":"7666_CR36","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1200\/JCO.2014.57.8963","volume":"33","author":"AK Turnbull","year":"2015","unstructured":"Turnbull AK, Arthur LM, Renshaw L, Larionov AA, Kay C, Dunbier AK, Thomas JS, Dowsett M, Sims AH, Dixon JM (2015) Accurate prediction and validation of response to endocrine therapy in breast cancer. J Clin Oncol 33(20):2270\u20132278","journal-title":"J Clin Oncol"},{"issue":"1","key":"7666_CR37","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13058-016-0748-7","volume":"18","author":"MJ Sikora","year":"2016","unstructured":"Sikora MJ, Jacobsen BM, Levine K, Chen J, Davidson NE, Lee AV, Alexander CM, Oesterreich S (2016) WNT4 mediates estrogen receptor signaling and endocrine resistance in invasive lobular carcinoma cell lines. Breast Cancer Res 18(1):92","journal-title":"Breast Cancer Res"},{"issue":"43","key":"7666_CR38","doi-asserted-by":"publisher","first-page":"E6600","DOI":"10.1073\/pnas.1612835113","volume":"113","author":"X Fu","year":"2016","unstructured":"Fu X, Jeselsohn R, Pereira R, Hollingsworth EF, Creighton CJ, Li F, Shea M, Nardone A, De Angelis C, Heiser LM et al (2016) FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer. Proc Natl Acad Sci U S A 113(43):E6600-e6609","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"25","key":"7666_CR39","doi-asserted-by":"publisher","first-page":"15292","DOI":"10.1074\/jbc.271.25.15292","volume":"271","author":"DM Ornitz","year":"1996","unstructured":"Ornitz DM, Xu J, Colvin JS, McEwen DG, MacArthur CA, Coulier F, Gao G, Goldfarb M (1996) Receptor specificity of the fibroblast growth factor family. J Biol Chem 271(25):15292\u201315297","journal-title":"J Biol Chem"},{"issue":"23","key":"7666_CR40","doi-asserted-by":"publisher","first-page":"15694","DOI":"10.1074\/jbc.M601252200","volume":"281","author":"X Zhang","year":"2006","unstructured":"Zhang X, Ibrahimi OA, Olsen SK, Umemori H, Mohammadi M, Ornitz DM (2006) Receptor specificity of the fibroblast growth factor family: the complete mammalian FGF family. J Biol Chem 281(23):15694\u201315700","journal-title":"J Biol Chem"},{"issue":"3","key":"7666_CR41","first-page":"840","volume":"62","author":"J Bange","year":"2002","unstructured":"Bange J, Prechtl D, Cheburkin Y, Specht K, Harbeck N, Schmitt M, Knyazeva T, M\u00fcller S, G\u00e4rtner S, Sures I et al (2002) Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res 62(3):840\u2013847","journal-title":"Cancer Res"},{"issue":"10","key":"7666_CR42","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1002\/cncr.11778","volume":"98","author":"Y Morimoto","year":"2003","unstructured":"Morimoto Y, Ozaki T, Ouchida M, Umehara N, Ohata N, Yoshida A, Shimizu K, Inoue H (2003) Single nucleotide polymorphism in fibroblast growth factor receptor 4 at codon 388 is associated with prognosis in high-grade soft tissue sarcoma. Cancer 98(10):2245\u20132250","journal-title":"Cancer"},{"issue":"7757","key":"7666_CR43","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-019-1186-3","volume":"569","author":"M Ghandi","year":"2019","unstructured":"Ghandi M, Huang FW, Jan\u00e9-Valbuena J, Kryukov GV, Lo CC, McDonald ER 3rd, Barretina J, Gelfand ET, Bielski CM, Li H et al (2019) Next-generation characterization of the cancer cell line encyclopedia. Nature 569(7757):503\u2013508","journal-title":"Nature"},{"issue":"1","key":"7666_CR44","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1158\/1078-0432.CCR-14-3212","volume":"22","author":"T Helsten","year":"2016","unstructured":"Helsten T, Elkin S, Arthur E, Tomson BN, Carter J, Kurzrock R (2016) The FGFR landscape in cancer: analysis of 4853 tumors by next-generation sequencing. Clin Cancer Res 22(1):259\u2013267","journal-title":"Clin Cancer Res"},{"issue":"6797","key":"7666_CR45","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/35021093","volume":"406","author":"CM Perou","year":"2000","unstructured":"Perou CM, S\u00f8rlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA et al (2000) Molecular portraits of human breast tumours. Nature 406(6797):747\u2013752","journal-title":"Nature"},{"issue":"1","key":"7666_CR46","doi-asserted-by":"publisher","first-page":"R41","DOI":"10.1530\/EJE-16-0124","volume":"175","author":"JS Carroll","year":"2016","unstructured":"Carroll JS (2016) Mechanisms of oestrogen receptor (ER) gene regulation in breast cancer. Eur J Endocrinol 175(1):R41-49","journal-title":"Eur J Endocrinol"},{"key":"7666_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2020.538734","volume":"11","author":"R Cheng","year":"2020","unstructured":"Cheng R, Qi L, Kong X, Wang Z, Fang Y, Wang J (2020) Identification of the significant genes regulated by estrogen receptor in estrogen receptor-positive breast cancer and their expression pattern changes when tamoxifen or fulvestrant resistance occurs. Front Genet 11:538734","journal-title":"Front Genet"},{"issue":"3","key":"7666_CR48","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1677\/joe.1.07016","volume":"191","author":"S Maor","year":"2006","unstructured":"Maor S, Mayer D, Yarden RI, Lee AV, Sarfstein R, Werner H, Papa MZ (2006) Estrogen receptor regulates insulin-like growth factor-I receptor gene expression in breast tumor cells: involvement of transcription factor Sp1. J Endocrinol 191(3):605\u2013612","journal-title":"J Endocrinol"},{"key":"7666_CR49","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1002\/jcb.1142","volume":"Suppl 36","author":"RI Yarden","year":"2001","unstructured":"Yarden RI, Wilson MA, Chrysogelos SA (2001) Estrogen suppression of EGFR expression in breast cancer cells: a possible mechanism to modulate growth. J Cell Biochem Suppl Suppl 36:232\u2013246","journal-title":"J Cell Biochem Suppl"},{"issue":"16","key":"7666_CR50","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1158\/0008-5472.CAN-23-0539","volume":"83","author":"Z Li","year":"2023","unstructured":"Li Z, Li T, Yates ME, Wu Y, Ferber A, Chen L, Brown DD, Carroll JS, Sikora MJ, Tseng GC et al (2023) The estrogene database reveals diverse temporal, context-dependent, and bidirectional estrogen receptor regulomes in breast cancer. Cancer Res 83(16):2656\u20132674","journal-title":"Cancer Res"},{"issue":"5","key":"7666_CR51","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1158\/0008-5472.CAN-09-3746","volume":"70","author":"N Turner","year":"2010","unstructured":"Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, Lopez-Garcia MA, Natrajan R, Marchio C, Iorns E, Mackay A et al (2010) FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res 70(5):2085\u20132094","journal-title":"Cancer Res"},{"issue":"21","key":"7666_CR52","doi-asserted-by":"publisher","first-page":"6443","DOI":"10.1158\/1078-0432.CCR-19-0138","volume":"25","author":"JZ Drago","year":"2019","unstructured":"Drago JZ, Formisano L, Juric D, Niemierko A, Servetto A, Wander SA, Spring LM, Vidula N, Younger J, Peppercorn J et al (2019) FGFR1 amplification mediates endocrine resistance but retains TORC sensitivity in metastatic hormone receptor-positive (HR(+)) breast cancer. Clin Cancer Res 25(21):6443\u20136451","journal-title":"Clin Cancer Res"},{"issue":"20","key":"7666_CR53","doi-asserted-by":"publisher","first-page":"6138","DOI":"10.1158\/1078-0432.CCR-17-1232","volume":"23","author":"L Formisano","year":"2017","unstructured":"Formisano L, Stauffer KM, Young CD, Bhola NE, Guerrero-Zotano AL, Jansen VM, Estrada MM, Hutchinson KE, Giltnane JM, Schwarz LJ et al (2017) Association of FGFR1 with ER\u03b1 maintains ligand-independent ER transcription and mediates resistance to estrogen deprivation in ER(+) breast cancer. Clin Cancer Res 23(20):6138\u20136150","journal-title":"Clin Cancer Res"},{"issue":"10","key":"7666_CR54","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.neo.2017.07.006","volume":"19","author":"L Turczyk","year":"2017","unstructured":"Turczyk L, Kitowska K, Mieszkowska M, Mieczkowski K, Czaplinska D, Piasecka D, Kordek R, Skladanowski AC, Potemski P, Romanska HM et al (2017) FGFR2-driven signaling counteracts tamoxifen effect on ER\u03b1-positive breast cancer cells. Neoplasia 19(10):791\u2013804","journal-title":"Neoplasia"},{"issue":"22","key":"7666_CR55","doi-asserted-by":"publisher","first-page":"5974","DOI":"10.1158\/1078-0432.CCR-19-3958","volume":"26","author":"P Mao","year":"2020","unstructured":"Mao P, Cohen O, Kowalski KJ, Kusiel JG, Buendia-Buendia JE, Cuoco MS, Exman P, Wander SA, Waks AG, Nayar U et al (2020) Acquired FGFR and FGF alterations confer resistance to estrogen receptor (ER) targeted therapy in ER(+) metastatic breast cancer. Clin Cancer Res 26(22):5974\u20135989","journal-title":"Clin Cancer Res"},{"issue":"5","key":"7666_CR56","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0036713","volume":"7","author":"DM French","year":"2012","unstructured":"French DM, Lin BC, Wang M, Adams C, Shek T, H\u00f6tzel K, Bolon B, Ferrando R, Blackmore C, Schroeder K et al (2012) Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models. PLoS ONE 7(5):e36713","journal-title":"PLoS ONE"},{"issue":"12","key":"7666_CR57","doi-asserted-by":"publisher","first-page":"13575","DOI":"10.18632\/oncotarget.6185","volume":"7","author":"H Zhao","year":"2016","unstructured":"Zhao H, Lv F, Liang G, Huang X, Wu G, Zhang W, Yu L, Shi L, Teng Y (2016) FGF19 promotes epithelial-mesenchymal transition in hepatocellular carcinoma cells by modulating the GSK3\u03b2\/\u03b2- catenin signaling cascade via FGFR4 activation. Oncotarget 7(12):13575\u201313586","journal-title":"Oncotarget"},{"issue":"1","key":"7666_CR58","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1038\/s41467-022-30217-7","volume":"13","author":"Y Zou","year":"2022","unstructured":"Zou Y, Zheng S, Xie X, Ye F, Hu X, Tian Z, Yan SM, Yang L, Kong Y, Tang Y et al (2022) N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer. Nat Commun 13(1):2672","journal-title":"Nat Commun"},{"key":"7666_CR59","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S H\u00e4nzelmann","year":"2013","unstructured":"H\u00e4nzelmann S, Castelo R, Guinney J (2013) GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics 14:7","journal-title":"BMC Bioinformatics"},{"issue":"7403","key":"7666_CR60","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nature10983","volume":"486","author":"C Curtis","year":"2012","unstructured":"Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y et al (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486(7403):346\u2013352","journal-title":"Nature"},{"issue":"1","key":"7666_CR61","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson MD, McCarthy DJ, Smyth GK (2010) edgeR: a bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26(1):139\u2013140","journal-title":"Bioinformatics"},{"issue":"2","key":"7666_CR62","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s10549-012-2377-x","volume":"137","author":"P Jambal","year":"2013","unstructured":"Jambal P, Badtke MM, Harrell JC, Borges VF, Post MD, Sollender GE, Spillman MA, Horwitz KB, Jacobsen BM (2013) Estrogen switches pure mucinous breast cancer to invasive lobular carcinoma with mucinous features. Breast Cancer Res Treat 137(2):431\u2013448","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"7666_CR63","doi-asserted-by":"publisher","first-page":"7205","DOI":"10.1038\/s41598-018-25357-0","volume":"8","author":"T Du","year":"2018","unstructured":"Du T, Zhu L, Levine KM, Tasdemir N, Lee AV, Vignali DAA, Houten BV, Tseng GC, Oesterreich S (2018) Invasive lobular and ductal breast carcinoma differ in immune response, protein translation efficiency and metabolism. Sci Rep 8(1):7205","journal-title":"Sci Rep"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-025-07666-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-025-07666-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-025-07666-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T04:02:32Z","timestamp":1744862552000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-025-07666-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,17]]},"references-count":63,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["7666"],"URL":"https:\/\/doi.org\/10.1007\/s10549-025-07666-x","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,17]]},"assertion":[{"value":"7 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All clinical samples were collected with approval from the Institutional Review Board (IRB) at the University of Pittsburgh.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All clinical samples were collected with informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}